Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet E Pope

Showing results (21-30 of 299) with videos related to

Pageof 30
Sort By:
The Lancet. Rheumatology|January 17, 2024
How low can we go for continued dosing of rituximab in rheumatoid arthritis?Janet E Pope
RMD Open|May 10, 2020
Management of Fatigue in Rheumatoid ArthritisJanet E Pope
Current Treatment Options in Rheumatology|May 2, 2020
What Does the COVID-19 Pandemic Mean for Rheumatology Patients?Janet E Pope
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Editorial: Safety of Tumor Necrosis Factor Inhibitors in PregnancyJanet E Pope
Rheumatology (Oxford, England)|March 27, 2012
Survival is improving in systemic sclerosis: true or false?Janet E Pope
The Journal of Rheumatology|February 3, 2020
Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into UptakeJanet E Pope
Nature Reviews. Rheumatology|August 21, 2023
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?Janet E Pope
Nature Reviews. Rheumatology|June 10, 2022
To choose or not? The value of discrete-choice experiments in rheumatologyJanet E Pope
Rheumatology (Oxford, England)|September 11, 2019
What is the best treatment for early rheumatoid arthritis?Janet E Pope
The Lancet. Rheumatology|January 24, 2024
The future of treatment in systemic sclerosis: can we design better trials?Janet E Pope
Pageof 30

Showing results (21-30 of 299) with videos related to

Sort By:
Pageof 30
The Lancet. Rheumatology|January 17, 2024
How low can we go for continued dosing of rituximab in rheumatoid arthritis?Janet E Pope
RMD Open|May 10, 2020
Management of Fatigue in Rheumatoid ArthritisJanet E Pope
Current Treatment Options in Rheumatology|May 2, 2020
What Does the COVID-19 Pandemic Mean for Rheumatology Patients?Janet E Pope
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Editorial: Safety of Tumor Necrosis Factor Inhibitors in PregnancyJanet E Pope
Rheumatology (Oxford, England)|March 27, 2012
Survival is improving in systemic sclerosis: true or false?Janet E Pope
The Journal of Rheumatology|February 3, 2020
Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into UptakeJanet E Pope
Nature Reviews. Rheumatology|August 21, 2023
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?Janet E Pope
Nature Reviews. Rheumatology|June 10, 2022
To choose or not? The value of discrete-choice experiments in rheumatologyJanet E Pope
Rheumatology (Oxford, England)|September 11, 2019
What is the best treatment for early rheumatoid arthritis?Janet E Pope
The Lancet. Rheumatology|January 24, 2024
The future of treatment in systemic sclerosis: can we design better trials?Janet E Pope
Pageof 30